ClinicalTrials.gg
RecruitingNCT05298124MINOSUpdated May 6, 2026

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

An interventional study of Transcatheter edge-to-edge repair and Medical therapy in Cardiogenic Shock and Mitral Regurgitation, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Canada — 6 open to participants now, 7 under way, none of them phase 3. Shock, Cardiogenic · Canada.

Started
2022
with 2 others
No phase
Only one
of the 13
Registered
7th of 13
by date
Lead sponsor
4 of 13
Ottawa Heart Institute Research Corporation

Among the 13 studies in Shock, Cardiogenic with a site in Canada, this one is one of 3 that started in 2022, is the only one with no phase, and was the 7th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

6 of the 13 studies in Shock, Cardiogenic with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Canada, or all of them as a file.
02

Study summary

Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.

This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.

The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?"

The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.

Read the detailed description

Current management strategies for patients with SCAI stage C through E cardiogenic shock include management in a cardiac intensive care unit (CICU) or cardiac surgery intensive care unit (CSICU) with intravenous inotropes (i.e. medications to increase the pumping function of the heart), vasopressors (i.e. medications to increase blood pressure), ventilatory support, and/or mechanical circulatory support. Importantly, with the exception of revascularization, little data exists demonstrating the ability to alter prognosis in patients with cardiogenic shock.

Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.

This study will be divided into two phases, as follows:

Phase 1 (Vanguard) - The first phase of this study will be composed of a feasibility stage where a total of 10 participants from centers in Ontario, Canada will be recruited. The primary objective of this phase is to ascertain feasibility of participant recruitment and treatment. Feasibility would be considered met if 10 participants were enrolled 12 months from the date of activation of all four centers.

Phase 2 - The second phase of this study will be a continuation of Phase 1 where the remaining 134 participants, for a total of 144 participants in the overall study. For this second phase of the study, patients will be recruited from high-volume TEER centers in Canada and the United States - with participating centers performing more than 25 TEER procedures per year.

Eligible participants will be randomly assigned in a 1:1 fashion to the medical therapy arm (i.e. control arm) or the TEER arm (i.e. intervention arm) of the trial.

03

Conditions studied

  • Cardiogenic Shock
  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants or substitute decision maker is able and willing to provide written
  2. Age ≥ 18 years
  3. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization
  4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)
  5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \<3+ MR

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to obtain from the participant or substitute decision maker
  2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization
  3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention
  4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)
  5. Echocardiographic evidence of left sided intracardiac mass or thrombus
  6. Diagnosis of active infective endocarditis
  7. Transesophageal echocardiogram is
  8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team
  9. Any aortic valve disease greater than moderate in severity
  10. A known or contraindication to procedure medications which cannot be adequately managed medically
  11. Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery
  12. Plan for durable mechanical circulatory support implantation prior to TMVr
  13. In the opinion of the treating team, there is a significant comorbidity that would limit in hospital
  14. Pregnant or planning to become pregnant in the next 6 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Transcatheter edge-to-edge repair

    The experimental arm includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support plus transcatheter edge-to-edge repair

    Device: Transcatheter edge-to-edge repair

  • Active comparator
    Medical therapy

    Medical therapy includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support.

    Other: Medical therapy

Interventions

  • DeviceTranscatheter edge-to-edge repair

    Transcatheter edge-to-edge repair

    Also known as: MitraClip

  • OtherMedical therapy

    Medical treatment in an intensive care unit

06

What researchers measure

Primary outcomes

  1. Primary composite outcome

    The primary outcome in this clinical trial will be a composite of in-hospital all-cause mortality, cardiac transplantation, implantation of durable LVAD, or discharge on palliative inotropic therapy.

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

Secondary outcomes

  1. In hospital all-cause mortality

    Death from any cause

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  2. In hospital implantation of durable left-ventricular assist device or cardiac transplantation

    Implantation of durable left-ventricular assist device or cardiac transplantation

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  3. Discharge on inotropes

    Discharge from index hospitalization on palliative inotropic therapy

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  4. Residual mitral regurgitation

    Severity of residual mitral regurgitation as assessed by the core lab on last available in hospital echocardiogram

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  5. Technical success

    All of the following must be present: I. Absence of procedural mortality II. Successful access, delivery, and retrieval of the device delivery system III. Successful deployment and correct positioning of the first intended device IV. Freedom from emergency surgery or reintervention related to the device or access procedure.

    Time frame: Measured at exit from procedure room, generally 2 hours after implant

  6. Device success

    All of the following must be present: I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure IV. Continued intended safety and performance of the device, including: A. No evidence of structural or functional failure B. No specific device-related technical failure issues and complications C. Reduction of mitral regurgitation to either optimal or acceptable levels without significant mitral stenosis, and with no greater than mild (1+) paravalvular mitral regurgitation (and without associated hemolysis)

    Time frame: At time of discharge from hospitalization, generally up to 12 weeks following admission

  7. Stroke or transient ischemic attack

    Acute episode of a focal or global neurological deficit as determined by or in conjunction with the designated neurologist

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  8. Bleeding

    * Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI) * Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit * Fatal bleeding (bleeding that directly results in death within 7 d)

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  9. Vascular access complications

    Access site-related arterial or venous injury or injury to surrounding structures

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

  10. Cardiac structural complications

    Cardiac perforation or pseudoaneurysm

    Time frame: Through duration of hospitalization, generally up to 12 weeks following admission

Other outcomes

  1. All-cause mortality

    Death from any cause

    Time frame: 6 months

  2. All-cause hospitalization

    Hospitalization is defined as admission to an inpatient unit or ward in the hospital for ≥24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition.

    Time frame: 6 months

  3. Any re-intervention on the mitral valve

    Requiring any transcatheter or surgical re-intervention on the mitral valve

    Time frame: 6 months

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The IPD sharing plan is to be decided upon at trial completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2028, 72 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 72 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Mar 28, 2022
StartActual
May 26, 2022
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05298124
Responsible party
Sponsor
First posted
Mar 28, 2022
Start date
May 26, 2022
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
May 6, 2026

Study contacts

Benjamin Hibbert, MD PhD
Contact
bhibbert@ottawaheart.ca
613-696-7115
Pietro Di Santo, MD
Contact
pdisanto@ottawaheart.ca
613-696-7000 ext. 15258

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion